1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Vulvovaginal Candidiasis-Pipeline Insights, 2016

Vulvovaginal Candidiasis-Pipeline Insights, 2016

  • November 2016
  • -
  • Delve Insight
  • -
  • 60 pages


DelveInsight’s, “ Vulvovaginal Candidiasis-Pipeline Insights, 2016”, report provides in depth insights on the pipeline drugs and their development activities around the Vulvovaginal Candidiasis. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Vulvovaginal Candidiasis. DelveInsight’s Report also assesses the Vulvovaginal Candidiasis therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope
- The report provides competitivepipeline landscape of Vulvovaginal Candidiasis
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Vulvovaginal Candidiasis pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Vulvovaginal Candidiasis and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Table Of Contents

Vulvovaginal Candidiasis-Pipeline Insights, 2016

Illustrative Table of contents

- Vulvovaginal Candidiasis Overview
- Vulvovaginal Candidiasis Pipeline Therapeutics
- Vulvovaginal Candidiasis Therapeutics under Development by Companies
- Vulvovaginal Candidiasis Filed and Phase III Products
- Comparative Analysis
- Vulvovaginal Candidiasis Phase II Products
- Comparative Analysis
- Vulvovaginal Candidiasis Phase I and IND Filed Products
- Comparative Analysis
- Vulvovaginal Candidiasis Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Vulvovaginal Candidiasis - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Vulvovaginal Candidiasis - Discontinued Products
- Vulvovaginal Candidiasis - Dormant Products
- Companies Involved in Therapeutics Development for Vulvovaginal Candidiasis
- Appendix
- Methodology
- Contact Us
- Disclaimer

List of Tables

- Number of Products under Development for Vulvovaginal Candidiasis, 2016
- Number of Products under Development by Companies
- Comparative Analysis by Filed and Phase III Products, 2016
- Comparative Analysis Phase II Products, 2016
- Comparative Analysis Phase I and IND Filed Products, 2016
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2016
- Drug Candidates Profiles
- Vulvovaginal Candidiasis Assessment by Monotherapy Products
- Vulvovaginal Candidiasis Assessment by Combination Products
- Vulvovaginal Candidiasis Assessment by Route of Administration
- Vulvovaginal Candidiasis Assessment by Stage and Route of Administration
- Vulvovaginal Candidiasis Assessment by Molecule Type
- Vulvovaginal Candidiasis Assessment by Stage and Molecule Type
- Vulvovaginal Candidiasis Therapeutics - Discontinued Products
- Vulvovaginal Candidiasis Therapeutics - Dormant Products
- Products under Development by Companies, 2016

List of Figures

- Number of Products under Development for Vulvovaginal Candidiasis, 2016
- Filed and Phase III Products, 2016
- Phase II Products, 2016
- Phase I and IND Filed Products, 2016
- Discovery and Pre-Clinical Stage Products, 2016
- Vulvovaginal Candidiasis Assessment by Monotherapy Products
- Vulvovaginal Candidiasis Assessment by Combination Products
- Vulvovaginal Candidiasis Assessment by Route of Administration
- Vulvovaginal Candidiasis Assessment by Stage and Route of Administration
- Vulvovaginal Candidiasis Assessment by Molecule Type
- Vulvovaginal Candidiasis Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Proteinuria Treatment Market: By Type (Angiotensin Converting Enzyme (ACE) Inhibitors, Aldosterone Antagonist (i.e., spironolactone), Angiotensin Receptor Blocker (ARB), and Others) & By Region-Forecast (2016-2021)

Proteinuria Treatment Market: By Type (Angiotensin Converting Enzyme (ACE) Inhibitors, Aldosterone Antagonist (i.e., spironolactone), Angiotensin Receptor Blocker (ARB), and Others) & By Region-Forecast (2016-2021)

  • $ 5250
  • Industry report
  • August 2016
  • by Industry ARC

Proteinuria is a result of an excess of serum proteins in the urine, which can led to renal damage. The most common cause of proteinuria is diabetes. Globally, development the arena of proteomics and ...

Benign prostatic hyperplasia (BPH)- Market Insights, Epidemiology and Market Forecast-2023

Benign prostatic hyperplasia (BPH)- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Benign prostatic hyperplasia (BPH) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of ...

Endometriosis- Market Insights, Epidemiology and Market Forecast-2023

Endometriosis- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Endometriosis - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global ...

Global Endometriosis Industry

October 2016 $ 4950

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.